BiotechTube

FT819 + Fludarabine + Cyclophosphamide + Bendamustine

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)

Conditions

Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)

Trial Timeline

Mar 28, 2024 → Sep 30, 2042

NCT ID
NCT06308978

About FT819 + Fludarabine + Cyclophosphamide + Bendamustine

FT819 + Fludarabine + Cyclophosphamide + Bendamustine is a phase 1 stage product being developed by Fate Therapeutics for Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06308978. Target conditions include Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc).

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06308978Phase 1Recruiting

Other Products from Fate Therapeutics

ProHema-CB + Untreated CBPhase 2
44
ProTmune + Control ArmPhase 1/2
33
Single FT1050 treated UCB unitPhase 1
25
ProHema-CB TransplantPhase 1
25
FT516 + Rituximab + Obinutuzumab + Cyclophosphamide + Fludarabine + IL-2 + BendamustinePhase 1
25